Compare Tidewater Inc (TDW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs 10X Genomics Inc — how do they compare? Tidewater Inc trades at $92.78 (market cap $4.58B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals.
| TDW | TXG | |
|---|---|---|
Market Cap | $4.58B | $8.55B |
Sector | Utilities | Health |
52-Week High | $100.61 | $67.29 |
52-Week Low | $47.29 | $11.34 |
Enterprise Value | $4.62B | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TDW trades at $92.00, down 2.4% on the day, with a bullish technical signal and support near $91. The company reported a net income of $334.66M in 2025, though 2026 earnings have missed expectations in two of the last three quarters. Recent news includes the completion of the Wilson Sons Ultratug acquisition (Business Wire, 2026-08-31), potentially expanding its offshore service capabilities.
The stock offers a 14.7% upside to the consensus price target of $105.50, supported by strong institutional interest, but faces risks from volatile earnings and competitive pressures in the energy sector. Profit margins are expected to compress in 2026, requiring careful monitoring of operational execution.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
